Wednesday, August 26, 2026

CMS has issued updated technical guidance on the enforcement timeline for its prior authorization transparency rules. The guidance clarifies the specific reporting deadlines and metrics that Medicare Advantage, Medicaid, and marketplace plans must meet under the No Surprises Act provisions. This move signals CMS's intent to begin active oversight of payer compliance with denial-rate disclosures and electronic PA standards. The final rule's effective date is January 1, 2027, but the agency is now outlining the phased reporting requirements. Monitor your major payers' portals for policy updates related to PA data submission and automated workflows as they prepare for these mandates.

A major Minneapolis hospital network has notified patients it will terminate its contract with UnitedHealthcare Medicare Advantage, effective January 1, 2027. This is a network exclusion, not a plan discontinuation. Patients will need to switch to a different Medicare Advantage plan that includes this hospital system in-network or return to Original Medicare during the upcoming Annual Enrollment Period. Practices in the Twin Cities region with a high volume of UHC MA patients must begin patient communications now. Update your front-office scripts for eligibility checks and prepare to assist patients with plan comparisons ahead of the October 15 enrollment window.

Waystar used its 2026 Investor Day to detail its push toward an autonomous revenue cycle management platform. The strategy hinges on AI and automation to handle tasks like claims editing, prior authorization, and denial prediction. The company specifically highlighted a goal to increase first-pass claim approval rates and reduce administrative costs for providers. This reflects a broader industry shift where major RCM vendors are competing on AI-driven workflow automation rather than just claims processing. While this is a vendor announcement, it signals the feature sets and pricing models practices will encounter in future RCM platform evaluations.

U.S. employers are preparing to cut coverage for GLP-1 weight-loss drugs next year as overall healthcare costs are projected to increase by nearly 10% in 2027. A separate report from AOL, citing a Willis Towers Watson survey, confirms employers are set to reduce coverage as costs soar. This signals a significant shift in employer-sponsored plans, potentially moving high-cost obesity and diabetes medications to higher-tier formularies or excluding them entirely. The cost pressure is driven by broader medical inflation and high drug utilization. For practices, this means more prior authorization hurdles and patient affordability conversations for drugs like semaglutide and tirzepatide. Monitor employer plan announcements and formulary changes during Q4 2026 open enrollment.

New data reveals the maternal healthcare access gap between urban and rural Texas has widened significantly, with rural counties experiencing higher rates of maternity care deserts and worse outcomes. This trend reflects a national pattern of rural healthcare erosion, exacerbated by Medicaid reimbursement rates, workforce shortages, and hospital closures. The disparity impacts patient volumes and payer mix for remaining rural providers, increasing the burden of uncompensated care and complicating referrals. For clinics in affected regions, this underscores the financial and operational strain of serving Medicaid and uninsured populations in resource-scarce areas. The data may inform state and federal policy debates on rural health funding and Medicaid expansion.